Cumberland Pharmaceuticals Inc (CPIX) - Net Assets
Based on the latest financial reports, Cumberland Pharmaceuticals Inc (CPIX) has net assets worth $21.30 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($71.00 Million) and total liabilities ($49.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CPIX intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $21.30 Million |
| % of Total Assets | 30.01% |
| Annual Growth Rate | 7.09% |
| 5-Year Change | -42.39% |
| 10-Year Change | -66.43% |
| Growth Volatility | 71.28 |
Cumberland Pharmaceuticals Inc - Net Assets Trend (2005–2025)
This chart illustrates how Cumberland Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See CPIX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cumberland Pharmaceuticals Inc (2005–2025)
The table below shows the annual net assets of Cumberland Pharmaceuticals Inc from 2005 to 2025. For live valuation and market cap data, see how much is Cumberland Pharmaceuticals Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $24.54 Million | +8.86% |
| 2024-12-31 | $22.55 Million | -22.95% |
| 2023-12-31 | $29.26 Million | -18.66% |
| 2022-12-31 | $35.97 Million | -15.56% |
| 2021-12-31 | $42.60 Million | -9.11% |
| 2020-12-31 | $46.87 Million | -8.24% |
| 2019-12-31 | $51.09 Million | -8.07% |
| 2018-12-31 | $55.57 Million | -13.06% |
| 2017-12-31 | $63.92 Million | -12.58% |
| 2016-12-31 | $73.12 Million | -4.82% |
| 2015-12-31 | $76.82 Million | -4.87% |
| 2014-12-31 | $80.75 Million | +1.84% |
| 2013-12-31 | $79.29 Million | -7.33% |
| 2012-12-31 | $85.57 Million | +3.30% |
| 2011-12-31 | $82.84 Million | +6.59% |
| 2010-12-31 | $77.72 Million | +7.61% |
| 2009-12-31 | $72.22 Million | +311.40% |
| 2008-12-31 | $17.55 Million | +4.83% |
| 2007-12-31 | $16.75 Million | +50.52% |
| 2006-12-31 | $11.13 Million | +78.48% |
| 2005-12-31 | $6.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cumberland Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1503968400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $51.68 Million | 207.73% |
| Total Equity | $24.88 Million | 100.00% |
Cumberland Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Cumberland Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ramssol Group Bhd
KLSE:0236
|
$68.49 Million |
|
TV Today Network Limited
NSE:TVTODAY
|
$68.51 Million |
|
Gseven Co Ltd
TWO:2937
|
$68.52 Million |
|
Xin Chio Global Co Ltd
TWO:3171
|
$68.59 Million |
|
Dagi Giyim Sanayi ve Ticaret AS
IS:DAGI
|
$68.45 Million |
|
GAMING INNOVATION DL 1
F:GI11
|
$68.43 Million |
|
TOPMATERIAL LTD
KQ:360070
|
$68.41 Million |
|
Crown Confectionery Co Ltd
KO:264900
|
$68.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cumberland Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 22,853,494 to 24,880,322, a change of 2,026,828 (8.9%).
- Net loss of 2,836,128 reduced equity.
- Share repurchases of 263,478 reduced equity.
- New share issuances of 5,266,334 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.84 Million | -11.4% |
| Share Repurchases | $263.48K | -1.06% |
| Share Issuances | $5.27 Million | +21.17% |
| Other Changes | $-139.90K | -0.56% |
| Total Change | $- | 8.87% |
Book Value vs Market Value Analysis
This analysis compares Cumberland Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.37x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 14.48x to 3.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $0.39 | $5.61 | x |
| 2006-12-31 | $0.68 | $5.61 | x |
| 2007-12-31 | $1.01 | $5.61 | x |
| 2008-12-31 | $1.06 | $5.61 | x |
| 2009-12-31 | $3.96 | $5.61 | x |
| 2010-12-31 | $3.69 | $5.61 | x |
| 2011-12-31 | $4.03 | $5.61 | x |
| 2012-12-31 | $4.33 | $5.61 | x |
| 2013-12-31 | $4.33 | $5.61 | x |
| 2014-12-31 | $4.51 | $5.61 | x |
| 2015-12-31 | $4.49 | $5.61 | x |
| 2016-12-31 | $4.50 | $5.61 | x |
| 2017-12-31 | $4.02 | $5.61 | x |
| 2018-12-31 | $3.58 | $5.61 | x |
| 2019-12-31 | $3.32 | $5.61 | x |
| 2020-12-31 | $3.10 | $5.61 | x |
| 2021-12-31 | $2.87 | $5.61 | x |
| 2022-12-31 | $2.49 | $5.61 | x |
| 2023-12-31 | $2.07 | $5.61 | x |
| 2024-12-31 | $1.63 | $5.61 | x |
| 2025-12-31 | $1.66 | $5.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cumberland Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.37%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 3.09x
- Recent ROE (-11.40%) is below the historical average (0.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 31.35% | 18.28% | 1.05x | 1.63x | $1.33 Million |
| 2006 | 39.59% | 24.72% | 0.67x | 2.38x | $3.29 Million |
| 2007 | 24.15% | 14.41% | 0.97x | 1.73x | $2.37 Million |
| 2008 | 27.15% | 13.59% | 1.13x | 1.77x | $3.01 Million |
| 2009 | 4.28% | 7.10% | 0.42x | 1.44x | $-4.13 Million |
| 2010 | 3.16% | 5.36% | 0.50x | 1.18x | $-5.32 Million |
| 2011 | 6.82% | 11.06% | 0.54x | 1.15x | $-2.64 Million |
| 2012 | 6.82% | 11.96% | 0.50x | 1.15x | $-2.73 Million |
| 2013 | -2.65% | -6.57% | 0.37x | 1.10x | $-10.05 Million |
| 2014 | 3.00% | 6.57% | 0.39x | 1.18x | $-5.65 Million |
| 2015 | 0.95% | 2.18% | 0.36x | 1.20x | $-6.95 Million |
| 2016 | -1.29% | -2.86% | 0.35x | 1.28x | $-8.26 Million |
| 2017 | -12.48% | -19.39% | 0.44x | 1.46x | $-14.37 Million |
| 2018 | -12.47% | -17.09% | 0.36x | 2.02x | $-12.55 Million |
| 2019 | -6.92% | -10.29% | 0.33x | 2.05x | $-8.65 Million |
| 2020 | -7.11% | -8.92% | 0.39x | 2.05x | $-8.04 Million |
| 2021 | -8.19% | -9.75% | 0.43x | 1.97x | $-7.79 Million |
| 2022 | -15.36% | -13.26% | 0.45x | 2.56x | $-9.20 Million |
| 2023 | -21.21% | -15.88% | 0.48x | 2.76x | $-9.24 Million |
| 2024 | -28.35% | -17.11% | 0.50x | 3.31x | $-8.77 Million |
| 2025 | -11.40% | -6.37% | 0.58x | 3.09x | $-5.32 Million |
Industry Comparison
This section compares Cumberland Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $379,169,986
- Average return on equity (ROE) among peers: -14.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cumberland Pharmaceuticals Inc (CPIX) | $21.30 Million | 31.35% | 2.33x | $68.47 Million |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $172.65 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $7.56 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $273.24 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $7.42 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $5.19 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $37.89 Million | 15.55% | 0.65x | $189.34 Million |
| ANI Pharmaceuticals Inc (ANIP) | $197.26 Million | 7.85% | 1.18x | $1.80 Billion |
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso… Read more